Tau PET Imaging in Corticobasal Syndrome represents a critical advancement in the in vivo assessment of tau pathology in CBS. Unlike postmortem studies, tau PET allows visualization of tau deposition during life, enabling differential diagnosis, disease monitoring, and assessment of therapeutic efficacy. This page covers the radiotracers, imaging findings, clinical applications, and limitations of tau PET in CBS.
1. Tau PET Radiotracers
1.1 First-Generation Tracers
Flortaucipir (AV-1451, [^18F]FTP)
Flortaucipir (also known as AV-1451 or [^18F]flortaucipir) is the most extensively studied tau PET tracer in neurodegenerative disease[^1]. Developed by Avid Radiopharmaceuticals, it binds to paired helical filament (PHF) tau with high affinity.
Binding mechanism: Flortaucipir binds to the microtubule-binding repeat domain of PHF-tau, showing selectivity for 3R and 4R tau aggregates
Off-target binding: Known off-target binding includes monoamine oxidase B (MAO-B) in the basal ganglia, neuromelanin in the substantia nigra, and off-target binding to amyloid plaques in some cases
Kinetics: Shows steady-state binding potential with reasonable test-retest reliability
Other First-Generation Tracers
[^18F]THK5351: Early tau PET tracer with off-target MAO-B binding
[^18F]THK5317 (S-AV-45): Enantiomer of THK5351 with improved binding characteristics
[^11C]PBB3: Second-generation tracer with broader tau binding profiles
1.2 Second-Generation Tracers
...
Tau PET Imaging in Corticobasal Syndrome
Overview
Tau PET Imaging in Corticobasal Syndrome represents a critical advancement in the in vivo assessment of tau pathology in CBS. Unlike postmortem studies, tau PET allows visualization of tau deposition during life, enabling differential diagnosis, disease monitoring, and assessment of therapeutic efficacy. This page covers the radiotracers, imaging findings, clinical applications, and limitations of tau PET in CBS.
1. Tau PET Radiotracers
1.1 First-Generation Tracers
Flortaucipir (AV-1451, [^18F]FTP)
Flortaucipir (also known as AV-1451 or [^18F]flortaucipir) is the most extensively studied tau PET tracer in neurodegenerative disease[^1]. Developed by Avid Radiopharmaceuticals, it binds to paired helical filament (PHF) tau with high affinity.
Binding mechanism: Flortaucipir binds to the microtubule-binding repeat domain of PHF-tau, showing selectivity for 3R and 4R tau aggregates
Off-target binding: Known off-target binding includes monoamine oxidase B (MAO-B) in the basal ganglia, neuromelanin in the substantia nigra, and off-target binding to amyloid plaques in some cases
Kinetics: Shows steady-state binding potential with reasonable test-retest reliability
Other First-Generation Tracers
[^18F]THK5351: Early tau PET tracer with off-target MAO-B binding
[^18F]THK5317 (S-AV-45): Enantiomer of THK5351 with improved binding characteristics
[^11C]PBB3: Second-generation tracer with broader tau binding profiles
1.2 Second-Generation Tracers
Second-generation tau PET tracers aim to improve specificity, kinetics, and reduce off-target binding:
[^18F]MK-6240: High affinity for PHF-tau, reduced off-target binding
[^18F]APN-1607 (Fluoro-PET): Pan-tau tracer with potential for different tau morphologies
[^18F]PI-2620: High binding to 3R/4R tau with favorable kinetics
[^18F]RO-948: Selective for PHF-tau with minimal off-target
2. Tau PET Findings in Corticobasal Syndrome
2.1 Regional Distribution Patterns
Tau PET in CBS shows characteristic patterns that differ from other tauopathies:
Asymmetric Cortical Pattern
CBS demonstrates asymmetric tau deposition reflecting the clinical asymmetry of the disease[^2]:
Predominant regions: Superior frontal gyrus, inferior parietal lobule, superior temporal gyrus
Asymmetry index: Higher contralateral-to-ipsilateral ratio compared to PSP
Motor cortex involvement: Primary motor and premotor cortex show significant uptake
Basal Ganglia and Midbrain
Globus pallidus: Variable uptake depending on underlying pathology
Substantia nigra: Variable binding due to neuromelanin off-target
Red nucleus: May show uptake in CBS with PSP pathology